European Journal of Clinical Pharmacology

, Volume 46, Issue 6, pp 523–526 | Cite as

Smoking and body weight influence the clearance of chlorpromazine

  • M. Chetty
  • R. Miller
  • S. V. Moodley
Originals

Abstract

The population pharmacokinetic parameters of chlorpromazine (CPZ) in chronic schizophrenic patients were evaluated using 189 plasma concentration measurements from 31 patients.

A NONMEM analysis demonstrated that the clearance of CPZ depended on the patient's body weight. Cigarette smoking and cannabis smoking increased the clearance of CPZ. Chronic alcohol consumption and the concurrent use of anticholinergics did not appear to influence the clearance of CPZ significantly.

Key words

Chlorpromazine Schizophrenic patients population pharmacokinetics clearance cigarette smoking cannabis smoking 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sramek JJ, Potkin SG, Hahn R (1988) Neuroleptic plasma concentrations and clinical response: in search of a therapeutic window. DICP 22: 373–380Google Scholar
  2. 2.
    Jones EE (1988) Chlorpromazine plasma level monitoring of schizophrenic patients. J Clin Pharm Ther 13: 385–387Google Scholar
  3. 3.
    May PRA, Van Putten T (1978) Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 35: 1081–1087Google Scholar
  4. 4.
    Cooper TB (1978) Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 3: 14–38Google Scholar
  5. 5.
    Curry SH, Marshall JHL (1968) Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatry patients. Life Sci 7: 9–17Google Scholar
  6. 6.
    Wode-Helgodt B, Borg S, Fyro B, Sedvall G (1978) Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with chlorpromazine. Acta Psychiatr Scand 58: 149–173Google Scholar
  7. 7.
    Beal SL, Sheiner B (1989) NONMEN Users Guide. 1. Users Basic Guide. Technical Report. Division of Clinical Pharmacology, University of California, San FranciscoGoogle Scholar
  8. 8.
    American Psychiatric Association (1980) DSM III Diagnostics and Statistical Manual of Mental Disorders, 3rd edn. American Psychiatric, Washington, DCGoogle Scholar
  9. 9.
    Chetty M, Miller R (1991) Effect of storage on the plasma concentration of chlorpromazine and six of its metabolites. Ther Drug Monit 3: 350–355Google Scholar
  10. 10.
    Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448Google Scholar
  11. 11.
    Graves NM, Ludden TM, Holmes GC, et al (1989) Pharmacokinetics of felbamate, a novel antiepileptic drug: applications of mixed effects modeling to clinical trials. Pharmacotherapy 9: 372–376Google Scholar
  12. 12.
    Gibalidi M, Perrier D (1982) Absorption kinetics and bioavailability. In: Swarbrick N (ed) Pharmacokinetics, 2nd ed. Dekker, New York, pp 192Google Scholar
  13. 13.
    Graves DA, Chang IH (1990) Applications of NONMEM to routine bioavailability, data. J Pharmacokinet Biopharm 18: 145–160Google Scholar
  14. 14.
    Young RC (1986) Plasma Nor1 chlorpromazine concentrations: Effects of age, race and sex. Ther Drug Monit 8: 23–26Google Scholar
  15. 15.
    Stimmel GL, Falloon IRH (1986) Chlorpromazine plasmal levels: adverse effects and tobacco smoking. J Clin Psychiatry 44: 420–422Google Scholar
  16. 16.
    Pantuck EJ, Pantuck CB, Anderson KK, Conney AH (1982) Cigarette smoking and chlorpromazine disposition. Clin Pharmacol Ther 31: 533–538Google Scholar
  17. 17.
    Sellers EM, Bendayan R (1987) Pharmacokinetics of psychotropic drug in selected patient populations. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1397–1406Google Scholar
  18. 18.
    Rivera-Calimlim L, Nasrallah H, Strauss J, Lasagna L (1976) Clinical response and plasma levels: effect of dose, dosage schedules and drug interactions. Am J Psychiatry 133: 646–652Google Scholar
  19. 19.
    Simpson GM, Cooper TP, Bark N, et al (1980) Effect of antiparkinsonian medication on plasma chlorpromazine levels. Arch Gen Psychiatry 37: 205–208Google Scholar
  20. 20.
    Rockland L, Cooper T, Schwartz E, et al (1990) Effects of trihexyphenidyl on plasma chlorpromalzine in young schizophrenia. Can J Psychiatry 35: 604–607Google Scholar
  21. 21.
    El-Youself MK, Manier DH (1974) Estrogen effects on phenothiazine derivative blood levels. JAMA 288: 827Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • M. Chetty
    • 1
  • R. Miller
    • 1
  • S. V. Moodley
    • 2
  1. 1.Drug Studies UnitUniversity of Durban-WestvilleDurbanSouth Africa
  2. 2.Fort Napier HospitalPietermaritzburgSouth Africa

Personalised recommendations